Company / Working Capital
Inhibikase Therapeutics, Inc. Working Capital History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$94.7M
FY2024
5-year range
$10.8M / $94.7M
FY2022-FY2024
Trend
+779.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital changed +779% YoY in FY2024, a notable deviation from the 2-year average annual change of +366%.
Based on SEC 10-K filings.
$95M in FY2024.
Improved from $21M to $95M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, working capital increased 779.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $94.7M | +779.3% |
| FY2023 | $10.8M | -47.9% |
| FY2022 | $20.7M | - |
| FY2021 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026